Skip to main content
. 2018 Aug 29;10:3069–3082. doi: 10.2147/CMAR.S159660

Figure 6.

Figure 6

WZ35 inhibits growth of gefitinib/erlotinib-resistant lung cancer growth in vivo. Nude mice bearing H1975 xenografts received 2.5 or 5 mg/kg WZ35 for 24 days. (AC) WZ35 treatment inhibits H1975 tumor growth as indicated by tumor volume (A), extracted tumor size (B), and tumor weight (C) (***P<0.001 compared to vehicle control; n=6). (D) Body weight changes of mice in the various experimental groups. (E) Western blot analysis on cleaved caspase 3 levels in lysates prepared from tumors. GAPDH was used as protein loading control. (F) H1975 tumor sections were stained with anti-Ki-67 (brown) to detect proliferating cells. Cells were counterstained with hematoxylin.